Market Research Report

Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022
cover Published by Visiongain
Published Product code 239211
Content info 223 Pages
Price

Introduction

Abstract

Report Details

image1

Generic drugs - discover potentials and revenue prospects of companies, seeing what the future holds

How are companies in the generics market performing? Visiongain's report gives you data, analyses and discussions for leading manufacturers of generic drugs.

That new study lets you assess prominent companies in the generics market from 2012 to 2022. See how companies worldwide are performing and where they are heading.

There, you find analytical profiles for leading producers - activities, outlooks and prospects:

  • Teva Pharmaceutical Industries
  • Sandoz
  • Mylan
  • Actavis
  • Hospira
  • Watson
  • Abbott
  • Sanofi
  • Ranbaxy
  • Cipla
  • Aspen
  • Stada Arzneimittel
  • Coverage of 38 other leading companies from around the world.

See how generics manufacturers compare, finding out how they can compete from 2012.

Our investigation gives you business research and analysis, including revenue forecasts to 2022. You discover commercial data, predictions and discussions for companies and the market in which they operate.

Where is the generics market heading? Many opportunities exist, especially in Japan and developing countries. Generic substitution is rising in Europe and the US.

Also, which producers will expand beyond their domestic and regional markets to become global forces for the manufacturing and sales of generic drugs? As our study shows, there are many companies breaking into new markets and expanding generic product ranges.

Complex generics, with high market entry barriers, and biosimilar (follow-on biologic/protein) products will transform the generics industry and pharma markets. Many opportunities exist for drug companies with biotechnological capabilities. Our report shows and explains.

The patent cliff will result in many more of the pharmaceutical industry's blockbusters being opened to generic competition. Which generic drug producers can best seize opportunities from 2012 to 2022? You find answers now in our study.

Company analysis, revenue forecasts and discussions of industry prospects

In visiongain's report you find historical revenues, sales predictions, growth rates and market breakdowns. Also, you see discussions of companies, product portfolios and growth potential. You receive 215 tables and charts.

Ten ways Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:

  • Assess 50 leading generics producers, discovering their activities and outlooks
  • Discover market leaders in each region
  • Receive analyses of leading companies, seeing revenue forecasts to 2022
  • View a comparative analysis of generics players
  • Assess commercial prospects, market breakdowns and product offerings
  • Find existing revenues and operational data for leading companies
  • Review technological, regulatory and commercial developments, assessing trends and prospects
  • Analyse prospects for generic drug launches
  • Investigate competition and opportunities influencing revenues
  • Find out what will stimulate and restrain the industry and market.

There, you find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

Gain business research and analysis on generic drug makers now

Our study is for everybody needing industry and market analyses for generic drug companies. You find data, trends and answers there. Please order that report now.

Table of Contents

Table of Contents

1. Executive Summary

  • 1.1 Overview of Findings
  • 1.2 Chapter Breakdown
  • 1.3 Research and Analysis Methods
  • 1.4 Scope of this Report
  • 1.5 Overview: Top 50 Generic Drug Manufacturers

2. The Leading Generic Drug Manufacturer: Teva Pharmaceutical Industries, 2012-2022

  • 2.1 Teva's Generics Business, 2012
  • 2.2 Regional Sales for Teva Generics, 2010-2011
  • 2.3 Teva's M&A Strategy, 2012
  • 2.4 Growth Forecast for Teva, 2012-2022

3. The Leading Big Pharma Generic Drug Manufacturers, 2012-2022

  • 3.1 Novartis (Sandoz), 2012
    • 3.1.1 Novartis' Generics Business, 2012
    • 3.1.2 Sales Breakdown for Novartis Generics, 2010-2011
    • 3.1.3 Growth Strategy for Novartis Generics, 2012-2022
    • 3.1.4 Growth Forecast for Novartis Generics, 2012-2022
  • 3.2 Abbott Laboratories, 2012
    • 3.2.1 Abbott's Generics Business, 2012
    • 3.2.2 Abbott's Position in the Emerging Markets, 2012
    • 3.2.3 Growth Forecast for Abbott Generics, 2012-2022
  • 3.3 Pfizer, 2012
    • 3.3.1 Pfizer's Generics Business, 2012
    • 3.3.2 Pfizer's Generics Growth Strategy, 2012
    • 3.3.3 Growth Forecast for Pfizer Generics, 2012-2022
  • 3.4 Sanofi, 2012
    • 3.4.1 Sanofi's Generics Business, 2012
    • 3.4.2 Sanofi's Generics Growth Strategy, 2012
    • 3.4.3 Growth Forecast for Sanofi Generics, 2012-2022
  • 3.5 Takeda, 2012
    • 3.5.1 Business Segments of Nycomed, 2011

4. The Leading North American Generic Drug Manufacturers, 2012-2022

  • 4.1 Mylan, 2012
    • 4.1.1 Mylan's Generics Business, 2012
    • 4.1.2 Mylan's Regional Presence, 2012
    • 4.1.3 Growth Forecast for Mylan Generics, 2012-2022
  • 4.2 Hospira, 2012
    • 4.2.1 Hospira's Generics Business, 2012
    • 4.2.2 Hospira Growth Strategies, 2012
    • 4.2.3 Growth Forecast for Hospira Generics, 2012-2022
  • 4.3 Watson Pharmaceuticals, 2012
    • 4.3.1 Watson's Generics Business, 2012
    • 4.3.2 Watson's Growth Strategies, 2012
    • 4.3.3 Growth Forecast for Watson Generics, 2012-2022
  • 4.4 Par Pharmaceutical, 2012
    • 4.4.1 Par's Generics Business, 2012
    • 4.4.2 Par's Growth Strategy, 2012
    • 4.4.3 Litigation Involving Par to 2012
  • 4.5 Apotex, 2012
    • 4.5.1 Apotex's Generics Business, 2012
    • 4.5.2 Apotex in the Canadian Generics Market, 2012
    • 4.5.3 Key Apotex Generic Launches, 2011
  • 4.6 Impax Laboratories, 2012
    • 4.6.1 Impax's Generics Business, 2012
  • 4.7 Covidien (Mallinckrodt), 2012
  • 4.8 Pharmascience, 2012
    • 4.7.1 Mallinckrodt Generics, 2012
    • 4.7.2 Litigation Involving Mallinckrodt
    • 4.8.1 Pharmascience's Generics Business, 2012
    • 4.8.2 Pharmascience's Growth Strategies, 2012
  • 4.9 Perrigo Company, 2012
    • 4.9.1 Perrigo's Generics Business, 2012
    • 4.9.2 Growth Prospects for Perrigo's Generics Business, 2012
  • 4.10 Hi-Tech Pharmacal, 2012
    • 4.10.1 Hi-Tech's Generics Business, 2012
    • 4.10.2 Growth Prospects for Hi-Tech, 2012
  • 4.11 Other North American Generics Companies, 2012

5. The Leading European Generic Drug Manufacturers, 2012-2022

  • 5.1 Actavis, 2012
    • 5.1.1 Actavis' Generics Business, 2012
    • 5.1.2 Actavis' Generics Growth Strategy, 2012
    • 5.1.3 Growth Forecast for Actavis Generics, 2012-2022
  • 5.2 Fresenius Kabi, 2012
    • 5.2.1 Fresenius Kabi's Generics Business, 2012
    • 5.2.2 Growth Strategies for Fresenius Kabi, 2012
    • 5.2.3 Growth Forecast for Fresenius Kabi Generics, 2012-2022
  • 5.3 Stada Arzneimittel, 2012
    • 5.3.1 Stada's Generics Business, 2012
    • 5.3.2 Stada's Growth Prospects, 2012
    • 5.3.3 Growth Forecast for Stada Arzneimittel Generics, 2012-2022
  • 5.4 Gedeon Richter, 2012
    • 5.4.1 Gedeon Richter's Generics Business, 2012
    • 5.4.2 Regional Presence of Gedeon Richter, 2012
    • 5.4.3 Growth Forecast for Gedeon Richter Generics, 2012-2022
  • 5.5 Krka, 2012
    • 5.5.1 Krka's Generics Business, 2012
    • 5.5.2 Krka's Business Growth, 2012
    • 5.5.3 Growth Forecast for Krka Generics, 2012-2022
  • 5.6 Alapis, 2012
    • 5.6.1 Alapis' Generics Business, 2012
    • 5.6.2 Alapis and the Greek Economic Crisis, 2009-2012
  • 5.7 Pharmstandard, 2012
    • 5.7.1 Pharmstandard's Generics Business, 2012
    • 5.7.2 Pharmstandard's Growth Prospects, 2012
  • 5.8 Egis Pharmaceuticals, 2012
    • 5.8.1 Egis' Generics Business, 2012
    • 5.8.2 Egis' Business Strategy, 2012
  • 5.9 Angelini, 2012
    • 5.9.1 Angelini's Generics Business, 2012
  • 5.10 Orion, 2012
    • 5.10.1 Orion's Generics Business, 2012
    • 5.10.2 Orion's Regional Strategy, 2012
  • 5.11 Bilim Pharmaceuticals, 2012
    • 5.11.1 Bilim's Generics Business, 2012
    • 5.11.2 Growth Prospects for Bilim
  • 5.12 Veropharm, 2012
    • 5.12.1 Growth Prospects for Veropharm's Generics Business, 2012
  • 5.13 Elpen Pharmaceutical, 2012
    • 5.13.1 Elpen's Generics Business, 2012
  • 5.14 Eastpharma, 2012
    • 5.14.1 Eastpharma's Generics Business, 2012
  • 5.15 Other European Generics Companies, 2012

6. The Leading Indian Generic Drug Manufacturers, 2012-2022

  • 6.1 Ranbaxy Laboratories, 2012
    • 6.1.1 Ranbaxy's Generics Business, 2012
    • 6.1.2 Ranbaxy's Growth Ambitions, 2012
    • 6.1.3 Growth Forecast for Ranbaxy Generics, 2012-2022
  • 6.2 Cipla, 2012
    • 6.2.1 Cipla's Generics Business, 2012
    • 6.2.2 Cipla and Patent Controversies, 2012
    • 6.2.3 Growth Forecast for Cipla Generics, 2012-2022
  • 6.3 Dr. Reddy's Laboratories, 2012
    • 6.3.1 Dr. Reddy's Generics Business, 2012
    • 6.3.2 Dr. Reddy's Regional Focus, 2012
    • 6.3.3 Growth Forecast for Dr. Reddy's Generics, 2012-2022
  • 6.4 Sun Pharma, 2012
    • 6.4.1 Sun's Generics Business, 2012
    • 6.4.2 Sun's Exports, 2012
    • 6.4.3 Growth Forecast for Sun Pharma Generics, 2012-2022
  • 6.5 Lupin, 2012
    • 6.5.1 Lupin's Generics Business, 2012
    • 6.5.2 Lupin's Regional Expansion, 2012
    • 6.5.3 Growth Forecast for Lupin Generics, 2012-2022
  • 6.6 Wockhardt, 2012
    • 6.6.1 Wockhardt's Generics Business, 2012
  • 6.7 Aurobindo, 2012
    • 6.7.1 Aurobindo's Generics Business, 2012
  • 6.8 Zydus Cadila, 2012
    • 6.8.1 Zydus Cadila's Generics Business, 2012
  • 6.9 Biocon, 2012
    • 6.9.1 Biocon's Generics Business, 2012
    • 6.9.2 Biocon's Collaborations, 2012
  • 6.10 Strides Arcolab, 2012
    • 6.10.1 Strides' Generics Business, 2012
    • 6.10.2 Strides' Business Partnerships, 2012
  • 6.11 Glenmark Pharmaceutical, 2012
    • 6.11.1 Glenmark's Generics Business, 2012
    • 6.11.2 Future Business Direction for Glenmark, 2012
  • 6.12 Other Indian Generics Manufacturers, 2012

7. The Leading Generic Drug Manufacturers in the Rest of the World, 2012-2022

  • 7.1 Aspen Pharma, 2012
    • 7.1.1 Aspen's Generics Business, 2012
    • 7.1.2 Aspen's Regional Presence, 2012
    • 7.1.3 Growth Forecast for Aspen Pharma Generics, 2012-2022
  • 7.2 Hikma Pharmaceuticals, 2012
    • 7.2.1 Hikma's Generics Business and Growth Prospects, 2012
  • 7.3 Sawai Pharmaceutical, 2012
    • 7.3.1 Sawai's Generics Business and Prospects, 2012
  • 7.4 Nichi-Iko Pharmaceutical Co., 2012
    • 7.4.1 Nichi-Iko's Generic Business and Prospects, 2012
  • 7.5 Towa Pharmaceutical, 2012
    • 7.5.1 Towa's Generics Business and Prospects, 2012
  • 7.6 Nippon Chemiphar, 2012
    • 7.6.1 Chemiphar's Generics Business and Prospects, 2012
  • 7.7 LG Life Sciences, 2012
    • 7.7.1 LG Life Sciences' Generics Business and Prospects, 2012
  • 7.8 EMS Sigma, 2012
    • 7.8.1 EMS Sigma's Generics Business and Prospects, 2012
  • 7.9 Eurofarma, 2012
    • 7.9.1 Eurofarma's Generics Business and Prospects, 2012

List of Tables

  • Table 1.1 Top 50 Generic Pharmaceutical Manufacturers: Revenues ($m) and Ranking, 2010
  • Table 2.1 Teva Pharmaceutical Industries: Overview, 2010
  • Table 2.2 Top Ten Generics Sector M&A Deals (Teva Deals Highlighted), 2004-Q1 2012
  • Table 2.3 Teva Pharmaceutical Industries: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 2.4 Teva Pharmaceutical Industries: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 3.1 Novartis: Overview, 2010
  • Table 3.2 Novartis: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 3.3 Novartis: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 3.4 Abbott Laboratories: Overview, 2010
  • Table 3.5 Abbott: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 3.6 Abbott: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 3.7 Pfizer: Overview, 2010
  • Table 3.8 Pfizer: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 3.9 Pfizer: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 3.10 Sanofi: Overview, 2010
  • Table 3.11 Sanofi: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 3.12 Sanofi: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 3.13 Takeda: Overview, 2010
  • Table 4.1 Mylan: Overview, 2010
  • Table 4.2 Mylan: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 4.3 Mylan: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 4.4 Hospira: Overview, 2010
  • Table 4.5 Hospira: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 4.6 Hospira: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 4.7 Watson: Overview, 2010
  • Table 4.8 Some Key Watson Generic Products, 2012
  • Table 4.9 Watson: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 4.10 Watson: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 4.11 Par Pharmaceutical: Overview, 2010
  • Table 4.12 Apotex: Overview, 2010
  • Table 4.13 Impax Laboratories: Overview, 2010
  • Table 4.14 Covidien: Overview, 2010
  • Table 4.15 Mallinckrodt Covidien Speciality Generics: Some Key Product Families, 2012
  • Table 4.16 Pharmascience: Overview, 2010
  • Table 4.17 Pharmascience Product Dossiers Registered in One or More EU State, 2012
  • Table 4.18 Perrigo Company: Overview, 2010
  • Table 4.19 High-Tech Pharmacal: Overview, 2010
  • Table 4.20 Selected Other North American Generic Companies, 2012
  • Table 5.1 Actavis: Overview, 2010
  • Table 5.2 Actavis: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 5.3 Actavis: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 5.4 Fresenius Kabi: Overview, 2010
  • Table 5.5 Fresenius Kabi: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 5.6 Fresenius Kabi: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 5.7 Stada Arzneimittel: Overview, 2010
  • Table 5.8 Stada: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 5.9 Stada: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 5.10 Gedeon Richter: Overview, 2010
  • Table 5.11 Gedeon Richter: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 5.12 Gedeon Richter: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 5.13 Krka: Overview, 2010
  • Table 5.14 Krka: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 5.15 Krka: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 5.16 Alapis: Overview, 2010
  • Table 5.17 Pharmstandard: Overview, 2010
  • Table 5.18 Egis: Overview, 2010
  • Table 5.19 Angelini: Overview, 2010
  • Table 5.20 Italian Drug Reimbursement Classes, 2012
  • Table 5.21 Orion: Overview, 2010
  • Table 5.22 Bilim Pharmaceuticals: Overview, 2010
  • Table 5.23 Veropharm: Overview, 2010
  • Table 5.24 Elpen Pharmaceutical: Overview, 2010
  • Table 5.25 Leading Elpen Generics, 2011
  • Table 5.26 EastPharma Pharmaceutical: Overview, 2010
  • Table 5.27 Leading EastPharma Generics, 2011
  • Table 5.28 Selected Other European Generics Companies, 2012
  • Table 6.1 Ranbaxy: Overview, 2010
  • Table 6.2 Ranbaxy: Top 10 Products, 2010
  • Table 6.3 Ranbaxy: Top 10 Therapeutic Areas, 2010
  • Table 6.4 Ranbaxy: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 6.5 Ranbaxy: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 6.6 Cipla: Overview, 2010
  • Table 6.7 Cipla: Subsidiaries and Affiliates, 2010
  • Table 6.8 Cipla: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 6.9 Cipla: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 6.10 Dr. Reddy's: Overview, 2010
  • Table 6.11 Dr. Reddy's: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 6.12 Dr. Reddy's: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 6.13 Sun Pharma: Overview, 2010
  • Table 6.14 Sun Pharma: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 6.15 Sun Pharma: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 6.16 Lupin: Overview, 2010
  • Table 6.17 Lupin: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 6.18 Lupin: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 6.19 Wockhardt: Overview, 2010
  • Table 6.20 Aurobindo: Overview, 2010
  • Table 6.21 Zydus Cadila: Overview, 2010
  • Table 6.22 Biocon: Overview, 2010
  • Table 6.23 Strides Arcolab: Overview, 2010
  • Table 6.24 Glenmark: Overview, 2010
  • Table 7.1 Aspen Pharma: Overview, 2010
  • Table 7.2 Aspen: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
  • Table 7.3 Aspen: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 7.4 Hikma: Overview, 2010
  • Table 7.5 Sawai: Overview, 2010
  • Table 7.6 Nichi-Iko: Overview, 2010
  • Table 7.7 Towa: Overview, 2010
  • Table 7.8 Nippon Chemiphar: Overview, 2010
  • Table 7.9 LG Life Sciences: Overview, 2010
  • Table 7.10 EMS Sigma: Overview, 2010
  • Table 7.11 Eurofarma: Overview, 2010

List of Figures

  • Figure 2.1 Teva Pharmaceutical Industries: Business Segments Revenue Breakdown (%), 2010
  • Figure 2.2 Teva Pharmaceutical Industries: Generic Sales ($m), Regional Breakdown, 2011
  • Figure 2.3 Teva Pharmaceutical Industries: Generic Sales ($m), Quarterly Breakdown, 2011
  • Figure 2.4 Teva Pharmaceutical Industries: Generic Revenues ($m), 2010-2015
  • Figure 2.5 Teva Pharmaceutical Industries: Generic Revenues ($m), 2016-2022
  • Figure 3.1 Novartis: Business Segments Revenue Breakdown (%), 2011
  • Figure 3.2 Novartis: Generic Revenue Breakdown (%), 2011
  • Figure 3.3 Novartis: Generic Revenues ($m), 2010-2015
  • Figure 3.4 Novartis: Generic Revenues ($m), 2016-2022
  • Figure 3.5 Abbott: Business Segments Revenue Breakdown (%), 2010
  • Figure 3.6 Abbott: Generic Revenues ($m), 2010-2015
  • Figure 3.7 Abbott: Generic Revenues ($m), 2016-2022
  • Figure 3.8 Pfizer: Business Segments Revenue Breakdown (%), 2010
  • Figure 3.9 Pfizer: Generic Revenues ($m), 2010-2015
  • Figure 3.10 Pfizer: Generic Revenues ($m), 2016-2022
  • Figure 3.11 Sanofi: Pharmaceutical Business Segments Revenue Breakdown (%), 2010
  • Figure 3.12 Sanofi: Generic Revenues ($m), 2010-2015
  • Figure 3.13 Sanofi: Generic Revenues ($m), 2016-2022
  • Figure 4.1 Mylan: Revenue Breakdown by Therapeutic Area (%), 2011
  • Figure 4.2 Mylan: Revenue Breakdown by Business Segment (%), 2011
  • Figure 4.3 Mylan: Generic Revenues ($m), 2010-2015
  • Figure 4.4 Mylan: Generic Revenues ($m), 2016-2022
  • Figure 4.5 Hospira: Revenue Breakdown by Business Segment (%), 2010
  • Figure 4.6 Hospira: Specialty Injectables Revenue Breakdown by Region (%), 2010
  • Figure 4.7 Hospira: Generic Revenues ($m), 2010-2015
  • Figure 4.8 Hospira: Generic Revenues ($m), 2016-2022
  • Figure 4.9 Watson: Revenue Breakdown by Business Segment (%), 2010
  • Figure 4.10 Watson: Generic Revenues ($m), 2010-2015
  • Figure 4.11 Watson: Generic Revenues ($m), 2016-2022
  • Figure 4.12 Par Generics: Revenue Breakdown by Customer (%), 2010
  • Figure 4.13 Generic Share in Canadian Market by Revenue (%), 2010
  • Figure 4.14 Generic Share in Canadian Market by Prescription Volume (%), 2005-2010
  • Figure 4.15 Impax Sales Channel Revenue Breakdown (%), 2010
  • Figure 4.16 Impax Generics: Revenue Breakdown by Customer (%), 2010
  • Figure 4.17 Perrigo Company: Revenue Breakdown by Business Segment (%), 2011
  • Figure 4.18 Hi-Tech Pharmacal: Revenue Breakdown by Business Segment (%), 2010
  • Figure 5.1 Actavis: Generic Revenues ($m), 2010-2015
  • Figure 5.2 Actavis: Generic Revenues ($m), 2016-2022
  • Figure 5.3 Fresenius SE: Revenue Breakdown by Company (%), 2011
  • Figure 5.4 Fresenius Kabi: Revenue Breakdown by Business Segment (%), 2010
  • Figure 5.5 Fresenius Kabi: Revenue Breakdown by Region (%), 2011
  • Figure 5.6 Fresenius Kabi: Generic Revenues ($m), 2010-2015
  • Figure 5.7 Fresenius Kabi: Generic Revenues ($m), 2016-2022
  • Figure 5.8 Stada: Revenue Breakdown by Business Segment (%), 2010
  • Figure 5.9 Stada: Distribution of Costs (%), 2010
  • Figure 5.10 Stada: Revenue Breakdown by Region (%), 2010
  • Figure 5.11 Stada: Generic Revenues ($m), 2010-2015
  • Figure 5.12 Stada: Generic Revenues ($m), 2016-2022
  • Figure 5.13 Gedeon Richter: Ownership of the Company (%), 2012
  • Figure 5.14 Gedeon Richter: Revenue Breakdown by Business Segment, 2010
  • Figure 5.15 Gedeon Richter: Revenue Breakdown by Therapeutic Area, 2010
  • Figure 5.16 Gedeon Richter: Revenue Breakdown by Region, 2010
  • Figure 5.17 Gedeon Richter: Generic Revenues ($m), 2010-2015
  • Figure 5.18 Gedeon Richter: Generic Revenues ($m), 2016-2022
  • Figure 5.19 Krka: Revenue Breakdown by Business Segment, 2011
  • Figure 5.20 Krka: Revenue Breakdown by Region, 2010
  • Figure 5.21 Krka: Revenue Breakdown by Therapeutic Area, 2010
  • Figure 5.22 Krka: Generic Revenues ($m), 2010-2015
  • Figure 5.23 Krka: Generic Revenues ($m), 2016-2022
  • Figure 5.24 Russian Pharmaceutical Market: Segmentation (%), 2010
  • Figure 5.25 Leading Companies in the Russian Pharmaceutical Market: Market Share (%), 2010
  • Figure 5.26 Egis: Revenue Breakdown by Therapeutic Class, FY 2011
  • Figure 5.27 Egis: Revenue Breakdown by Region, FY 2011
  • Figure 5.28 Orion: Revenue Breakdown by Business Segment, 2011
  • Figure 5.29 Orion: Revenue Breakdown by Region, 2011
  • Figure 5.30 Turkish Pharmaceutical Market: Generic and Originator Products Share of Market by Volume (%), 2010
  • Figure 5.31 Turkish Pharmaceutical Market: Generic and Originator Products Share of Market by Revenue (%), 2010
  • Figure 5.32 Veropharm: Leading Prescription Drugs, Company Revenue Share (%), H1 2011
  • Figure 5.33 Veropharm: Traditional Products, Company Revenue Share (%), H1 2011
  • Figure 5.34 Veropharm: OTC Products, Company Revenue Share (%), H1 2011
  • Figure 5.35 Russia's Hospital Oncology Market: Leading Companies by Share (%), H1 2011
  • Figure 6.1 Ranbaxy: Revenue Breakdown by Region (%), 2010
  • Figure 6.2 Ranbaxy: Approvals and Filings by Region, 2010
  • Figure 6.3 Ranbaxy: Generic Revenues ($m), 2010-2015
  • Figure 6.4 Ranbaxy: Generic Revenues ($m), 2016-2022
  • Figure 6.5 Cipla: Export Revenues Breakdown by Region (%), 2010
  • Figure 6.6 Cipla: Generic Revenues ($m), 2010-2015
  • Figure 6.7 Cipla: Generic Revenues ($m), 2016-2022
  • Figure 6.8 Dr. Reddy's: Revenue Breakdown by Business Segment (%), 2010
  • Figure 6.9 Dr. Reddy's: Top Indian Generics Brands, Revenue Share (%) 2010
  • Figure 6.10 Dr. Reddy's: Revenue Breakdown by Region (%), 2010
  • Figure 6.11 Dr. Reddy's: Generic Revenues ($m), 2010-2015
  • Figure 6.12 Dr. Reddy's: Generic Revenues ($m), 2016-2022
  • Figure 6.13 Sun Pharma: Revenue Breakdown (%) by Business Segment, 2010
  • Figure 6.14 Sun Pharma: Indian Generics Revenue Breakdown (%) by Therapeutic Area, 2010
  • Figure 6.15 Sun Pharma: Cumulative ANDA Filings and Approvals, 2004-2011
  • Figure 6.16 Sun Pharma: Generic Revenues ($m), 2010-2015
  • Figure 6.17 Sun Pharma: Generic Revenues ($m), 2016-2022
  • Figure 6.18 Lupin: Breakdown by Business Segment, 2010
  • Figure 6.19 Lupin: Business Segment Share of Revenues (%), Lupin FY 2007-2011
  • Figure 6.20 Lupin: Export Markets Share of Revenues (%), Lupin FY 2007-2011
  • Figure 6.21 Lupin: Generic Revenues ($m), 2010-2015
  • Figure 6.22 Lupin: Generic Revenues ($m), 2016-2022
  • Figure 6.23 Wockhardt: Generic Revenues Breakdown by Region (%), 2010
  • Figure 6.24 Aurobindo: Generic Revenues Breakdown by Region (%), 2010
  • Figure 6.25 Aurobindo: Generic Drug Submissions and Approvals, Breakdown by Region (%), 2010
  • Figure 6.26 Zydus Cadila: Generic Revenues Breakdown by Region (%), 2010
  • Figure 6.27 Biocon: Revenue Breakdown by Business Segment, 2010
  • Figure 6.28 Strides Arcolab: ANDA Submissions and Approvals, Company FY 2005-2010
  • Figure 6.29 Glenmark: Revenue Breakdown by Business Segment (%), 2010
  • Figure 6.30 Glenmark: Generic Revenue Breakdown by Segment (%), 2010
  • Figure 7.1 Aspen Revenues Breakdown by Region (%), 2011
  • Figure 7.2 Aspen Revenue Growth by Region (%), 2011
  • Figure 7.3 South African Market by Company Share (%), June 2011
  • Figure 7.4 Aspen's Latin American Revenues: Breakdown by Country (%), June 2011
  • Figure 7.5 Aspen: Generic Revenues ($m), 2010-2015
  • Figure 7.6 Aspen: Generic Revenues ($m), 2016-2022
  • Figure 7.7 Hikma: Revenue Breakdown by Business Segment, 2010
  • Figure 7.8 Hikma: Revenue Breakdown by Region, 2010
  • Figure 7.9 Sawai: Revenue Breakdown by Therapeutic Class, 2010
  • Figure 7.10 Sawai: Revenue Breakdown by Sales Channel, 2010
  • Figure 7.11 Nichi-Iko Generic Portfolio: Breakdown by Formulation, 2010
  • Figure 7.12 Nichi-Iko AGR (%), Company FY 2001-2010
  • Figure 7.13 Towa Revenue Breakdown by Therapeutic Class (%), FY 2010
  • Figure 7.14 Nippon Chemiphar Generic Revenues as Share of Overall Revenues, Company FY 2007-2010
  • Figure 7.15 Brazilian Pharmaceutical Market by Segment, 2010

Companies Listed

  • AA Pharma
  • Abbott Laboratories
  • Able Labs
  • Abraxis Bioscience
  • Abrika Pharmaceuticals
  • Aceto Corporation
  • Actavis
  • Active Pharma
  • Adcock Ingram
  • Aegera Therapeutics
  • Alapis
  • Alcon
  • Alfred E. Tiefenbacher
  • Almirall Prodesfarma
  • Alnylam Pharmaceuticals
  • Alphapharm
  • Alpharma
  • Altra Investments
  • Amerigen Pharmaceuticals
  • AmerisourceBergen
  • Amgen
  • Amide Pharmaceutical
  • Amneal Pharmaceuticals
  • Amylin Pharmaceuticals
  • Anadys Pharmaceuticals
  • Ancraf
  • Andrx Corporation
  • Angelini
  • Angenerico
  • Apicore
  • ApoPharma
  • Apotex
  • APP Pharmaceuticals
  • Aprogen
  • aRigen Pharmaceuticals
  • Arrow Generics
  • Asahi Kasei Pharma Corporation
  • Ascent Pharmahealth
  • ASKA Pharmaceutical
  • Aspen Group
  • Aspen Pharma
  • Astellas
  • AstraZeneca
  • Aurobindo
  • AxiCorp Sapient Discovery
  • B. Braun Melsungen
  • Balkanpharma
  • Barr Pharmaceuticals
  • Baxter Healthcare
  • Baxter International
  • Bayer
  • Bayer Yakuhin
  • Bedford Laboratories
  • Beltapharm
  • Biddle Sawyer Corporation
  • Bilim Pharmaceuticals
  • Bioceuticals Arzneimittel
  • BioChimico
  • Biocon
  • Biogen Idec
  • biomo pharma
  • Bioniche Pharma
  • BioTech Pharma
  • BiotechCorp
  • Bioton
  • Biovail Laboratories
  • Biovena Pharma
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Bunker Industria Farmaceutica
  • Cadila Healthcare
  • Caraco Pharmaceutical Laboratories
  • Cardinal Health
  • CareFusion
  • Celgene Corporation
  • Celltrion
  • Center of Molecular Immunology (Cuba)
  • Cephalon
  • Chattem Chemicals
  • ChemGenex
  • Chon Kun Dang
  • Ciba-Geigy
  • CIMA Labs
  • Cipla
  • Claris Lifesciences
  • Clinton Foundation
  • Cobalt Laboratories
  • Colotech
  • Combino Pharm
  • CoPharma
  • Corporacion Infarmasa
  • Covidien
  • CSC Pharmaceuticals
  • CSFB Alternative Capital
  • CVS Pharmacy
  • Dabur Pharma
  • Daiichi Sankyo
  • Debiopharm
  • Delta Pharma
  • DepoMed
  • Dey Pharma
  • DoctorActive
  • Dr. Reddy's Laboratories
  • DuPont Crop Protection
  • DURECT Corporation
  • EastPharma
  • Ebewe Pharma
  • EBIK
  • Eden Biopharm
  • Egis Pharmaceuticals
  • Elan
  • Eli Lilly
  • Elpen Pharmaceutical
  • Elpharma
  • Emcure Pharmaceuticals
  • EMET Pharmaceuticals
  • EMS Sigma
  • Endo Pharmaceutical
  • Ethex Corporation
  • Eurodrug Laboratories
  • Eurofarma Laboratorios
  • European Central Bank
  • European Generic Medicines Association (EGA)
  • European Medicines Agency (EMEA/EMA)
  • Eximas
  • Fako Pharma
  • Faran Laboratories
  • Farmaprojects
  • Federal Court of Canada
  • Fidia farmaceutici
  • Filaxis
  • Fisiopharma
  • Food and Drug Administration (US FDA)
  • Fougera
  • Fournier
  • Fresenius Kabi
  • Fresenius Medical Care
  • Fuso Pharmaceutical Industries
  • G&W Laboratories
  • Galderma
  • Gedeon Richter
  • Genepharm Group
  • Genericon Pharma
  • Genericos Espanoles
  • Genertec Group
  • Genesoft
  • Genzyme
  • Germa Pharm
  • GlaxoSmithKline
  • Glenmark
  • Graceway Pharmaceuticals
  • Grindeks
  • Grunenthal
  • Grupo Azevedos
  • Gujarat Lyka Organics
  • Gyma
  • Health Canada
  • Helm Pharmaceuticals
  • Help
  • Helvepharm
  • Helvetia Pharma
  • Hexal
  • Hikma Pharmaceuticals
  • Hi-Tech Pharmacal
  • HLJ.Haerbin Phar
  • Hormosan Pharma
  • Hospira
  • HRA Pharma
  • Human Genome Sciences
  • Hungarian State Holding Company
  • Hypermarcas
  • Ibiopro Solutions
  • Impax Laboratories
  • Institut National de la Sante et de la Recherche Medicale (INSERM, France)
  • Institut Pasteur Korea
  • IntelliPharmaCeutics
  • International Monetary Fund
  • Invent Farma
  • IPR Pharmaceuticals
  • Italfarmaco
  • Itero Biopharmaceuticals
  • IVAX
  • Janssen
  • Javelin Pharmaceuticals
  • Johnson & Johnson
  • JS.L.Y.G. Hengr
  • JS Yangzijiang
  • Jubilant Life Science
  • Kendall
  • Kent Pharmaceuticals
  • Ke Lun Group
  • Kern Pharma
  • Kiadis Pharma
  • Kobrek Pharmaceuticals
  • Korea Research Institute of Bioscience and Biotechnology
  • Kowa Company
  • Krka
  • Kroger
  • KV Pharmaceuticals
  • Kyorin Pharmaceutical
  • Labesfal
  • Laboratoire Theramex
  • Laboratories Besins Iscovesco
  • Laboratorio Sanderson
  • Laboratorio Teuto Brasileiro
  • Laboratorios Cinf
  • Laboratorios Kendrick
  • LaborMed Pharma
  • Lamda Detergent
  • Lehigh Valley Technologies
  • LG Life Sciences
  • Lotos Laboratories
  • Lundbeck
  • Lupin
  • Madaus
  • Mallinckrodt
  • Masterleik
  • Matrix Laboratories
  • Mayne Pharma
  • McKesson Drug Company
  • Medco
  • Medeva Pharma
  • Medimpex
  • Medis
  • Medley
  • Medochemie
  • Meiji Seika Pharma
  • Menarini
  • Merck & Co.
  • Merck KGaA
  • Midlothian Laboratories
  • Millennium Pharmaceuticals
  • Milmet Labs
  • Mitani Sangyo
  • Mitsubishi Tanabe Pharma
  • MJ Pharma
  • MN Pharmaceuticals
  • Mochida Pharmaceutical
  • Moksha8 Pharmaceuticals
  • Momenta Pharmaceuticals
  • Multicare Pharmaceuticals
  • Mylan
  • Myrallis
  • Napp Pharmaceutical
  • Nellcor
  • neuraxpharm
  • Nichi-Iko Pharmaceutical Co.
  • Nihon Chouzai
  • Nippon Chemiphar
  • Nippon Kayaku
  • Nordic Capital
  • Normon
  • Novartis
  • Novel Laboratories
  • Novo Nordisk
  • Nycomed
  • Ohm Laboratories
  • Optimer Pharmaceuticals
  • Orchid Chemicals & Pharmaceuticals
  • Orion
  • Ortho-McNeil-Janssen
  • Paddock Laboratories
  • Pangeo
  • Par Pharmaceutical
  • Perlecan Pharma
  • Perrigo Company
  • Pfizer
  • Pharma Avalance
  • Pharma Dynamics
  • Pharmacia & Upjohn
  • PharmaPack International
  • Pharmascience
  • Pharmstandard
  • Phlox Pharma
  • Pinewood Laboratories
  • Piramal Healthcare Solutions
  • Pliva
  • Polfa Warszawa
  • Polifarma
  • Polpharma
  • Pozen
  • Pradeep Drug Company
  • Prazzi-Donaduzzi
  • Promius Pharma
  • Pronova BioPharma
  • ProStrakan
  • Purdue Pharma Products
  • Puritan-Bennett
  • Pymepharco
  • QRxPharma
  • Ranbaxy Laboratories
  • ratiopharm-Merckle Group
  • Rega Farma de Produtos
  • Remedica
  • Rheoscience
  • Rhodes Technologies
  • Ribbon
  • Richter-Helm Biologics
  • Rite Aid
  • Rivopharm
  • Robin Hood Holdings
  • Roche
  • Rohatyn Group
  • Ross Products
  • Safety Syringes
  • Safeway
  • Sagent Pharmaceuticals
  • Salomon Levin and Elstein
  • Samsung
  • Sandoz
  • Sanofi
  • Santarus
  • Sawai Pharmaceutical
  • Schering-Plough
  • Schwarz Pharma
  • Sekisui Medical
  • SeQuent Scientific
  • Servier
  • Shandong Luoxin PH
  • Shandong Ruiyang
  • Shandong Qilu
  • SH.Asia Pioneer PH
  • Shelys Pharmaceuticals
  • Shionogi Seiyaku Kabushki Kaisha
  • Sicor
  • Sindan
  • SK Chemicals
  • Solvay Pharmaceuticals
  • Somaxon Pharmaceuticals
  • Sovereign
  • Spear
  • Spirig Pharma
  • Stada Arzneimittel
  • Stiefel Research Australia
  • Streuli Pharma
  • Strides Arcolab
  • Sun Pharma
  • Synageva
  • Synthon Pharmaceutica
  • Syrrx
  • Taiyo
  • Takeda
  • Taro Pharmaceutical Industries
  • Teuto
  • Teva Pharmaceutical Industries
  • Teva-Kowa Pharma
  • Three Rivers
  • Tolmar
  • Towa Pharmaceutical
  • Triax Pharmaceuticals
  • Tris Pharma
  • UCB Manufacturing
  • Unimed Pharmaceuticals
  • United Nations (UN)
  • University of Aberdeen
  • University of Athens
  • University of Missouri
  • University of Thessaly
  • University of Tokyo
  • Valeant Pharmaceuticals
  • Valleylab
  • Velefarm
  • Veropharm
  • Versapharm
  • Veterin
  • Vianex
  • Vinchem
  • Walgreens
  • Walmart
  • Warner Chilcott
  • Watson Pharmaceuticals
  • West Ward
  • Winthrop
  • Wockhardt
  • World Health Organization (WHO)
  • Wyeth
  • Zentiva
  • Zhejiang Chiral Medicine Chemicals
  • Zhuhai Lizhu Group
  • ZiO Zdorovje
  • Zydus Cadila
  • Zydus Hospira Oncology

Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022 published by Visiongain in March 26, 2012. This report consists of 223 Pages and the price starts from US $ 2739.

Back to Top